Role of Bumetanide in Treatment of Autism

Phase 3

Recruiting

• Conditions: Autism
• Interventions: Drug: Placebo; Drug: Bumetanide

• Registration Number: NCT04766177
• Lead Sponsor: Sherief Abd-Elsalam

Brief Summary

Role of bumetanide in Autism

Detailed Description

Role of Bumetanide in Treatment of Autism spectrum disorder in children

Study Timeline

• Study Start: 2021-01-01
• Status Verified: 2021-02
• Study First Submitted: 2021-02-19
• Study First Submitted QC: 2021-02-19
• Last Update Submitted: 2021-02-19
• Study First Posted: 2021-02-23
• Last Update Posted: 2021-02-23
• Primary Completion: 2030-12-01
• Study Completion: 2030-12-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. All patients with ASD diagnosed by CARS rating Scale⩾30.
2. Age of patients range between (3-12) years.

Exclusion Criteria

• Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo twice daily
bumetanide group	Bumetanide	Bumetanide a dose of 0.5 mg twice per day

Primary Outcome Measures

Name	Time	Method
Number of patients with improved CARS score	6 months	the patients with improved CARS score

Trial Locations

Locations (1)

Sherief Abd-Elsalam; 🇪🇬 Tanta, Egypt